Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, ImmunityBio, Inc. (IBRX) has a Wall Street consensus price target of $11.00, based on estimates from 5 covering analysts. With the stock currently trading at $9.78, this represents a potential upside of +12.5%. The company has a market capitalization of $9.63B.
Analyst price targets range from a low of $7.00 to a high of $15.00, representing a 73% spread in expectations. The median target of $11.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IBRX trades at a trailing P/E of -15.8x. Analysts expect EPS to grow +20.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how IBRX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonImmunityBio, Inc. (IBRX) has a consensus 12-month price target of $11, implying 12.5% upside from $9.78. The 5 analysts covering IBRX see moderate appreciation potential.
IBRX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $11 implies 12.5% upside from current levels.
IBRX's current price is $9.78 with a consensus target of $11 (12.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $15 for IBRX, while the most conservative target is $7. The consensus of $11 represents the median expectation. These targets typically reflect 12-month expectations.
IBRX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IBRX stock forecast based on 5 Wall Street analysts shows a consensus price target of $11, with estimates ranging from $7 (bear case) to $15 (bull case). The median consensus rating is "Buy".
Wall Street analysts are optimistic on IBRX, with a "Buy" consensus rating and $11 price target (12.5% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IBRX analyst price targets range from $7 to $15, a 73% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11 consensus represents the middle ground.